Over the past decade, avian influenza (AI) has become a major health concern. The development of safe and effective vaccines against avian strains infecting people is important. The purpose of this study is to determine the safety of and immune response to a new AI vaccine in healthy adults against the H7N3 strain of avian influenza.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Safety, defined as the frequency of vaccine-related reactogenicity events that occur during the acute monitoring (inpatient) phase of the study
Timeframe: Daily for 9 days after vaccination
Immunogenicity, determined by anti-H7N3 antibody titer
Timeframe: Before the first vaccination, 28 days after the first vaccination but before the second vaccination, and 28 days after the second vaccination
Quantifying the amount of vaccine virus shed by each recipient; and determining the amount of serum and nasal wash antibody induced by the vaccine
Timeframe: Daily for 9 days after vaccination